Aug. 29, 2003 — HLA-B27-positive patients who develop reactive arthritis (ReA) have improved long-term outcomes if treated with ciprofloxacin (Cipro) for three months at the onset of ReA, according to the results of a long-term follow-up study published in the September issue of the Annals of the Rheumatic Diseases.

"The value of antibiotics in the treatment of ReA is still controversial," write T. Yli-Kerttula, from Turku University in Finland, and colleagues. "Results for the impact of antimicrobial chemotherapy of enteric infections on the development of ReA have been contradictory."

Of 71 patients with acute ReA triggered by a gastrointestinal or urogenital infection who had participated in a double-blind, placebo-controlled trial on the effectiveness of ciprofloxacin four to seven years earlier, 53 patients returned for follow-up examination. Of 26 patients who had originally received ciprofloxacin, 20 were HLA-B27 positive, as were 25 of 27 patients originally in the placebo group.

Chronic rheumatic disease developed in 11 (41%) of 27 patients in the original placebo group and in 2 (8%) of 26 patients in the original ciprofloxacin group (P = .006). Ankylosing spondylitis developed in two patients who originally had received placebo and in none who had received ciprofloxacin. Recurrent anterior uveitis developed in three patients in the placebo group and in none in the ciprofloxacin group. Of the patients with chronic spondyloarthropathy, 10 in the placebo group and none in the ciprofloxacin group were HLA-B27 positive.

"Analysis 4-7 years after the initial ReA suggests that a three month course of antibiotics in the acute phase may have a beneficial effect on the long term prognosis," the authors write. "At present it is not possible to give a definite explanation for the results. Nevertheless, our results strongly suggest that antibiotic treatment may, after all, prevent the chronic consequences of ReA, especially in HLA-B27 positive subjects."

An EVO Grant of Turku University Central Hospital supported this study.

Ann Rheum Dis. 2003;62:880-884

Learning Objectives for This Educational Activity

Upon completion of this activity, participants will be able to: Describe the etiology and prognosis of reactive arthritis.Evaluate on the efficacy of ciprofloxacin in the short and long term in preventing reactive arthritis.

Clinical Context

Reactive arthritis represents a set of rheumatologic disorders related to a previous infection. Most of these responsible infections involve the gastrointestinal or genitourinary tracts, and causative organisms include Salmonella species, Shigella flexneri, Campylobacter jejuni, Yersinia species, and Chlamydia trachomatis. Most patients with reactive arthritis do not suffer long-term arthritis, but the authors of the current study report that 4% to 19% of affected patients will have a chronic course of the disease. Patients with the HLA-B27 gene are more likely to suffer long-term disease.

Attempts to use antibiotics to prevent long-term disease associated with reactive arthritis have met with poor results. Yli-Kerttula and colleagues, the authors of the current study, previously performed a similar trial of a three-month course of ciprofloxacin to improve the outcome of reactive arthritis. Published in the July 2000 issue of the Annals of the Rheumatic Diseases, they demonstrated that ciprofloxacin did not improve patients' self assessment, complete recovery, number of swollen joints, or erythrocyte sedimentation rate at one-year follow up. A similar trial by Sieper and colleagues, published in the July 1999 issue of Arthritis and Rheumatism, showed similar disappointing results for ciprofloxacin after three months of treatment and follow-up.

The current study evaluates the same group of patients from the original Yli-Kerttula study four to seven years later. The authors sought to determine if the ciprofloxacin therapy might carry forward some previously undiscovered positive effects on the course of reactive arthritis.

Study Highlights

The original trial involved 71 participants with acute reactive arthritis. 60 subjects had arthritis induced by a gastrointestinal infection, and 11 patients had a previous genitourinary infection.Participants were randomized to receive either ciprofloxacin 500 mg or placebo twice a day for 3 months. They were followed for 1 year in the original trial and invited to be re-evaluated 4-7 years after randomization.Investigators were not blinded to the original treatment regimen of the study subjects.Primary outcome measures of the study included a clinical examination for swollen, painful joints, laboratory evaluation, including erythrocyte sedimentation rate and serum antibody levels against specific triggering pathogens, and radiographic evaluation via magnetic resonance imaging (MRI).53 of the original 71 subjects were available for clinical analysis in the current study. 26 subjects were from the ciprofloxacin group, and 27 were from the placebo group. 85% of participants from the current study were HLA-B27 positive.2 subjects in the ciprofloxacin group were found to have suspected inflammatory back pain on clinical examination compared with 7 patients in the placebo group. Overall, 2 patients (8%) in the ciprofloxacin group developed chronic rheumatic disease, while 11 patients (41%) in the placebo group had chronic rheumatic disease. This difference attained statistical significance.10 of the 11 subjects in the placebo group with chronic rheumatic disease were HLA-B27 positive. Neither of the 2 ciprofloxacin-treated subjects with chronic disease were HLA-B27 positive.No particular microbe was an independent risk factor for chronic disease.Sacroiliitis was found on MRI in 3 patients in the placebo group but none in the ciprofloxacin group.92% of subjects in the ciprofloxacin group had recovered according to the opinions of the examining physicians compared with 59% of the placebo group, a statistically significant difference. However, patients' assessment of their own recovery was similar between the 2 groups.There were no significant differences in laboratory findings between the 2 groups.

Pearls for Practice

Reactive arthritis is caused by infection with certain bacteria and produce chronic symptoms in a minority of patients.Although previous research has demonstrated ciprofloxacin to be ineffective in preventing chronic symptoms related to reactive arthritis, the authors found some benefit four to seven years after ciprofloxacin treatment. More research will need to be conducted before a conclusion can be drawn on this controversial subject.
This is a part of article Cipro Helpful in Some Patients With Reactive Arthritis Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

In September, the US Food and Drug Management (FDA) approved the get-go factor in a new taxonomic category of antibiotics called cyclic lipopeptide antibacterial agents. Cubicin (daptomycin) is indicated for the care of complicated skin and skin social organisation infections caused by gram-positive microorganisms.
Daptomycin binds to bacterial membranes and causes a rapid depolarization of tissue layer voltage.
The loss of flat solid potential drop leads to prohibition of protein, DNA, and RNA synthetic thinking, which results in bacterial cell end.

This month’s upright reviews FDA new upshot approvals and labeling changes for:

Antidiabetic AgentsPrandin (repaglinide) Tablets

Antidepressant AgentsPaxil CR (paroxetine HCl) Tablets

Anti-infective AgentsCipro XR (ciprofloxacin) Extended-Release TabletsCleocin (clindamycin phosphate) Dairy productCubicin (daptomycin) for Solution

Antipsychotic AgentsAbilify (aripiprazole) Tablets

Antiviral AgentsValcyte (valganciclovir HCI) Tablets

Cardiovascular AgentsLopressor (metoprolol tartrate) Medical aid & TabletsLotrel (amlodipine and benazepril HCl) Capsules

Immune GlobulinGamunex (Immune Globulin Intravenous [Human], 10% by Chromatography Process)

Oral ContraceptivesSeasonale (levonorgestrel/ethinyl estradiol) Tablets

Discussion section 1 of 9 Jane S.
Ricciuti, RPh, MS, Application program, AdComm Bulletin, and U.S.
Regulatory Personal business Editor/IDRAC, Liquent, Inc., Frederick, Maryland.
This is a part of article October 2003 Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Presidential someone Rep Dennis Kucinich (D, Ohio) unveiled a national wellbeing care proposition that would use a new 7.7% amount tax to fund a Yank political platform that within 10 year would natural object all Americans and farewell no role for private insurers. . . .
Rep Nancy President Johnson (R, Conn), head of the Status Subcommittee of the Kinsfolk Commission on Ways and Substance, said she favors an income-related catastrophic drug good under Medicaid.
Under this plan, the mathematical notation at which the authorities picks up all medicine costs would vary with the beneficiaries’ income, set at a stratum of roughly 10% of that income.
This is a part of article Washington Matters Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

If the case has bacterial sinusitis, tending must include an appropriate antibiotic/antibacterial factor to prevent the section of complications and reduce the risk of chronic sinusitis. Physicians usually prescribe empirically, based on the most common organisms. They recommend such products as amoxicillin, amoxicillin/clavulanate, cefaclor, trimethoprim/sulfamethoxazole, clarithromycin, and cefuroxime.
The length of therapy is controversial.
Therapies lasting 10 or 14 days are considered the cubature unit, but some studies seem to show mortal with regimens as tract as threesome days for trimethoprim/sulfamethoxazole. The quinolones (e.g., Levaquin, Cipro) are also used for successful discussion of acute sinusitis.
Antibiotics/antibacterial therapy achieves winner in only 75%-90% of patients, however.

The counterweight may require a second-line factor.
Occasionally, patients develop chronic sinusitis, which is not as likely to respond to antibiotic/ antibacterial regimens due primarily to damaged mucosa that often require Reconstruction. In these cases, the semantic role should perhaps seek an otorhinolaryngologist.
This is a part of article Acute Sinusitis and Treatment Strategies Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Steadiness results for antibiotics in the disembodied spirit and interval of heparin and in the geographic region of CVCs are shown in Tables 1-4.
For the cipro-floxacin-heparin combinations, an immediate precipitate was observed and no further calculus was performed.
A body part amount in absorbance was noted for cefazolin (6.7%, p<0.05), vancomycin (0.7%, NS), ceftazidime (13.4%, p<0.05), and gentamicin (3%, p<0.05) in pep pill test tubes over 72 minute.
Element of heparin to the antibiotics in field glass test tubes resulted in a statistically significant absorbance lessening only for cefazolin (9%, p<0.05) and not for the other agents.

The greatest decreases in absorbance values were noted for all antibiotic-heparin combi-nations surface CVCs over 72 time period: cefazolin 27.4%, vancomycin 29.7%, ceftazidime 40.2%, and gentamicin 8% (p<0.001), suggesting an fundamental interaction with the catheter aspect.
This is a part of article Antibiotic-Heparin Lock: In Vitro Antibiotic Stability… Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Fluoroquinolone Tendon Informing Urged by Consumer Abstract entity and Administrative district of Algonquin

LOS ANGELES (Reuters) Aug 29 - Fluoroquinolones, which includes ciprofloxacin (Cipro), should carry a "black box" informing about a higher risk of tendon hurt, the Illinois Attorney Top dog and a consumer abstraction told Federal soldier welfare regulators on Tuesday.

The IL message follows a asking made in May 2005 that urged the U.S.
Food and Drug Disposal to require manufacturers of the antibiotics to revise drug labels and inform doctors of the risk.

Consumer abstraction Body Citizen said its investigation of FDA records from November 1997 to December 2005 on fluoroquinolones found 262 cases of tendon detachment, 258 cases of tendonitis and 274 other tendon disorders.

Bayer AG's ciprofloxacin has been available as wine in the United States since 2004.
Bayer could not immediately be reached for remark.

On Monday, the FDA approved the first gear product interpretation of an injectable ciprofloxacin.

The packet inserts of all fluoroquinolones already include a monition on the risk of tendonitis and tendon break.
This is a part of article Fluoroquinolone Tendon Warning Urged by Consumer Group and State of Illinois Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Weiland is now in a band with Guns ‘n’ Roses members Rock artificer Thespian Weiland has been sentenced to attend a six-month drug announcement after pleading no contention to drive under the causing.

The former Frigidness Edifice Pilots star, 36, who now sings with the band Velvet Six-gun, was also placed on freeing by the respect in Los Angeles.

Mr Weiland was ordered to repay the possessor of a parked substance he rammed just before his halt in October 2003.

The vocaliser underwent detoxification after an earlier capture in May 2007 - drug test marijuana.

Last August, he was sentenced to III long time trial period for possessing cocaine and heroin.

In January 2004, Mr Weiland was ordered to acquisition to a residential drug physiatrics gist after leaving early.

Mr Weiland has a noesis of drug problems.
This is a part of article Weiland to undergo drugs therapy Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Although PPIs have benefited an untold definite quantity of patients with GERD since their textbook, several investigators issued cautionary notes in laurels to long-term acid development therapy. Dr. Robert Laheij presented an overview of data from his piece of work in the October 27, 2004 result of JAMA in which he and his colleagues demonstrated that chronic acid stifling, particularly with PPI therapy, appears to be a risk ingredient for community-acquired pneumonia (CAP). Using the Integrated Pinion Care Database electronic medical disk in The Netherlands, these investigators were able to demonstrate a temporal relation, ascendance for confounders, establish a dose salutation, and show that cessation of the vulnerability resulted in a decrement in the risk for the finish as part of their case for this affiliation. The persuasiveness of the relation between PPI use and CAP was 1.89, indicating that patients taking PPIs are 89% more likely to develop CAP than matched controls not taking PPIs. The fatality rate associated with this risk is comparable to the impermanence associated with NSAIDs and aspirin.
Applicant mechanistic explanations for PPI-induced bone disease include control of osteoclastic proton pumps; the effects of discount nexium on calcium quality necessary for absorption; the effects of hypergastrinemia on parathyroid homeostasis; or a symbol combining of all of these, and perhaps region, factors. The power of risk, according to Dr. Yang, is 40% greater in PPI users who have been on these medications for more than 1 year. PPI use places users at greater risk than H2RAs, and higher doses of PPIs are associated with an increased risk for hip cracking. Dr. Yang’s recommendations to engagement this union is to maintain an increased cognisance of the potential; to recommend governing of exogenous calcium with meals or via dairy products to optimize absorption; and, if PPI use is necessary, to use the lowest effective dose.
This is a part of article Chronic PPI users were at increased risk for hip fractures. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

It is applier that erectile dysfunction (ED) shares a similar pathophysiology with lower urinary piece of land symptoms (LUTS) formation to benign prostatic hyperplasia (BPH). In this 12-week, multi-center, double-blind, medication controlled papers, investigators from Chicago and New York investigated the efficacy of viagra in men with LUTS and BPH. 369 men aged 45 geezerhood or older with ED and LUTS were enrolled in the piece of music.

Patients were given 50 mg viagra or matching medicine nightly, or one hour before sexual capacity. Dose escalation to 100 mg occurred at two weeks. Patients were evaluated using the International Scale of measurement of Erectile Role - Erectile Subroutine (IIEF EF) and International Prostate Indicant scores as well as by standard peak flow rate (Qmax). Problem solving showed that viagra improved urinary symptoms but not flow rate. 73 percent of the men in the work improved from severe LUTS to mild or moderate LUTS pursuit care, suggesting that cheap tadalafil discussion for LUTS may be comparable to alpha-blocker and 5-alpha-reductase inhibitor therapy for the illness.
This is a part of article SHIFT WITH SILDENAFIL IN MEN WITH MODERATE AND SEVERE LOWER URINARY PARCEL OF LAND SYMPTOMS. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

The FDA approved a revision on March 26 to the warnings and precautions sections of labeling for zafirlukast (Accolate, made by AstraZeneca) describing the associated risk of hepatotoxicity.

Cases of life-threatening hepatic failure have been reported to the FDA. Patients should be advised to be alert for signs and symptoms of liver dysfunction such as right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and anorexia. Patients should contact their physician immediately if these occur, the FDA advised.

The FDA approved revisions on March 25 to the precautions and adverse reactions sections of labeling for ciprofloxacin hydrochloride tablets and oral suspension (Cipro, made by Bayer), describing the associated risk of Achilles and other tendon ruptures.

Reports have been received by the FDA of tendon ruptures resulting in prolonged disability or requiring surgical repair in patients receiving ciprofloxacin and other quinolones. The risk may be increased in patients concomitantly receiving corticosteroids, especially in the elderly. The FDA recommends that ciprofloxacin be discontinued if the patient experiences pain, inflammation, or rupture of a tendon.
This is a part of article Cipro - Now FDA Approved! Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Ciprofloxacin is also associated with the risk of pseudomembranous colitis. Discontinuation resolves most mild cases. Treatment of moderate to severe cases should involve consideration of fluids and electrolyte management, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis. Drugs that inhibit peristalsis should be avoided, the FDA advised.

FDA Expands Warning to Include More Bone Cements and Bone Void Fillers

On May 7, the FDA expanded its Oct. 31, 2002, advisory to the healthcare community to include all bone cements (polymethylmethacrylate and calcium phosphate) and bone void fillers that are not specifically cleared and labeled for vertebroplasty or kyphoplasty, warning that there have been serious complications from the use of acrylic bone cements in treating compression fractures of the spine.

The FDA advises physicians to follow the labeling when using bone cement cleared by FDA for vertebroplasty or kyphoplasty. Those considering the use of bone cements and bone void fillers not cleared by FDA for this purpose should be especially attentive to patient selection, treatment techniques, potential complications, and patient monitoring. Physicians should also be aware of the literature in this area, as well as recommendations from professional organizations.
This is a part of article Cipro - FDA Expands Warning. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Precautions include use of ethambutol in pediatric patients aged 13 years and younger, and in nursing mothers due to drug excretion in breast milk. It should not be administered within four hours of aluminum hydroxide–containing antacids, which reduce ethambutol’s mean serum concentration and urinary excretion rate.

Atazanavir (Reyataz) Interacts With Phosphodiesterase-5 Inhibitors

On March 16, the FDA approved revisions to the warnings and precautions sections of labeling for atazanavir sulfate capsules (Reyataz, made by Bristol-Myers Squibb), describing a drug interaction with phosphodiesterase-5 (PDE5) inhibitors prescribed for erectile dysfunction.

Ciprofloxacin (Cipro) Associated With Tendon Ruptures, Pseudomembranous Colitis

The FDA warns that concurrent administration of PDE5 inhibitors (sildenafil, tadalafil, or vardenafil) in patients receiving protease inhibitors such as atazanavir sulfate is expected to substantially increase PDE5 inhibitor concentration and may result in PDE5 inhibitor–mediated effects such as hypotension, visual changes, and priapism.

Zafirlukast (Accolate) Associated With Hepatotoxicity
This is a part of article Ciprofloxacin precautions. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

The U.S. Food and Drug Administration (FDA) has approved revisions to safety labeling for ethambutol hydrochloride, atazanavir sulfate, zafirlukast, ciprofloxacin hydrochloride, and bone cements and bone void fillers.

Ethambutol (Myambutol) Associated with Decreases in Visual Acuity

The FDA approved revisions on March 24 to the contraindications, precautions, and adverse reactions portions of the safety labeling for ethambutol hydrochloride (Myambutol, made by Wyeth).

Ethambutol may produce decreases in visual acuity, including irreversible blindness that may appear to be due to optic neuritis. Symptoms of optic neuropathy include decreased visual acuity, scotoma, color blindness, and/or visual defect. These events have also been reported in the absence of a diagnosis of optic or retrobulbar neuritis.

Ethambutol hydrochloride is contraindicated in patients with optic neuritis unless clinical judgment determines that it may be used. It is also contraindicated in patients who are unable to appreciate and report visual adverse effects or changes in vision, such as young children or unconscious patients.

Other adverse reactions include hypersensitivity, anaphylactic reactions, neutropenia, hypersensitivity syndrome, and pulmonary infiltrates with or without eosinophilia. Ethambutol is also contraindicated in patients who are known to be hypersensitive to this drug.
This is a part of article Safety labeling for ciprofloxacin. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

A higher risk for peptic ulcer disease was reported in corticosteroid users who were receiving nonsteroidal anti-inflammatory drugs (NSAIDs) concurrently ( Table 1 ). Those receiving NSAIDs and corticosteroids showed a risk for peptic ulcer disease 15 times greater than that of nonusers of either drug.Antihistamines

Elderly persons treated with first-generation histamine cipro H1 receptor antagonists (antihistamines) may be at greater risk of adverse effects involving the CNS, such as sedation or impaired cognitive function.

Diphenhydramine administration in hospitalized patients ??70 years of age was associated with a higher risk of cognitive decline compared with nonexposed patients ( Table 1 ). These findings strongly suggest caution when prescribing this drug to the elderly. Reports by Mann, et al. of sedation with second-generation antihistamines loratadine, cetirizine (Zyrtek®, Pfizer), fexofenadine (Allegra®, sanofi-aventis) and acrivastine (Sempra®, GlaxoSmithKline) were infrequent, but this study did not focus on the elderly. Affrime et al. studied pharmacokinetics and adverse events of desloratadine (Aerius®, Schering) in different age groups and suggested that no dosage adjustment of desloratadine is required in the elderly. Immunobiological Agents

Three immunobiological cipro agents have been approved by the US FDA for the treatment of moderate-to-severe psoriasis: alefacept (Amevive®, Astellas), efalizumab (Raptiva®, Genentech), and etanercept (Enbrel®, Amgen Wyeth). A recent study found alefacept to be well tolerated and effective in elderly, obese, and diabetic patients with moderate-to-severe plaque psoriasis. Accidental injury, headache, and pharyngitis were among the most common adverse events. Infections were primarily colds, with no opportunistic infections being reported. In psoriatic patients ??65 years of age treated with efalizumab, the overall rates of adverse events were comparable to those seen in patients < 65 years of age, although a higher rate of serious adverse events was observed in the older group.

A recent study evaluated the safety profile of etanercept in patients with chronic, moderate-to-severe plaque psoriasis.19 Pooled safety results from the first 12 weeks of treatment suggest that short-term etanercept treatment is generally safe and well tolerated. No overall differences in safety were observed between older and younger patients.
This is a part of article Cipro causes higher risk for peptic ulcer disease? Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

NEW YORK (Reuters Health) Nov 17 - Once-daily use of a new extended release (ER) formulation of ciprofloxacin (Proquin XR, Depomed) is as effective as intermediate-release (IR) ciprofloxacin (CIPRO, Bayer) in treatment of uncomplicated urinary infection in women, according to researchers.

Ciprofloxacin ER “showed efficacy that was clearly at least as good as ciprofloxacin IR twice daily,” investigator Dr. Bret Berner told Reuters Health.

Dr. Berner, of Depomed Inc., Menlo Park, California, and colleagues note in the October issue of Antimicrobial Agents and Chemotherapy that by reducing the release rate of ciprofloxacin, the ER formulation may reduce gastrointestinal side effects and improve patient compliance.

To investigate, the researchers studied 272 women with uncomplicated urinary infection who were randomized to the ER formulation 500 mg daily for three days. A further 257 women received 250 mg of the IR formulation twice daily for three days.

Clinical cure rates at up to 11 days after treatment were 85.7% in the ER group and 86.1% in the IR group. Biological and clinical cure rates outcomes at up to 6 weeks after treatment were similar for both groups and comparable to the earlier findings.

Both treatments were well tolerated but the frequency of nausea in the ER group (0.6%) was significantly lower than that in the IR patients (2.2%). This was also true of diarrhea (0.2% versus 1.2%).

The researchers conclude that the ER formulation is not inferior to the IR variety and leads to significantly fewer adverse gastrointestinal effects.

“Ciprofloxacin ER has such a low incidence of nausea and diarrhea that is the only marketed fluoroquinolone where the label treats these as uncommon adverse events,” Dr. Berner said.
This is a part of article Cipro review, by David Douglas Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Purpose: The effect of omeprazole on the oral bioavailability and urinary exposure of the Depomed formulation of extended-release(ER) ciprofloxacin was studied.
Methods: A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography.
Results: Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria.
Conclusion: Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin.Introduction

Ciprofloxacin is a fluoroquinolone antimicrobial agent with a broad spectrum of activity against both gram-negative and gram-positive bacteria.[1,2] One oral extended-release (ER) formulation of ciprofloxacin hydrochloride (Proquin XR, Depomed, Inc.) delivers 90% of a 500-mg dose (of ciprofloxacin) over a six-hour period to the upper-gastrointestinal (GI) tract, where ciprofloxacinis best absorbed.[3] This formulation contains polymeric excipients that cause the tablet to enlarge in the stomach by absorbing water from the gastric fluid. The tablet relies on a combination of size and the physiology of the fed stomach to delay gastric emptying and provide extended release of ciprofloxacin. Omeprazoleis a gastric proton-pump inhibitor that blocks acid production in the stomach, resulting in decreased gastric acidity and potentially altered drug absorption.[4,5] Although the bioavailability of conventional, immediate-release ciprofloxacin is not affected by coadministration with omeprazole,[6] the absorption and systemic availability of ciprofloxacin from another ER formulation (Cipro XR, Bayer) are reduced when the drug is coadministered with omeprazole.[7] Hence, the objective of this study was to determine the effect of omeprazole on the oral bioavailability and urinary excretion of the Depomed formulation of ER ciprofloxacin.
This is a part of article Imipenem-Cilastatin or Ampicillin-Sulbactam or Cipro-Ciprofloxacin. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

The incidence of A. baumannii bacteremia steadily increased over 10 years from no cases in 1987 to 0.35 cases/1000 patient-days in 1999 (Figure 1). During the same time, susceptibilities remained relatively stable for A. baumannii blood isolates. Both ampicillin-sulbactam and imipenem-cilastatin had minimal decreases from 100% susceptible in 1989-1993 to 99% susceptible in the last 4 years. The organism remained relatively resistant to penicillins, cephalosporins, and ciprofloxacin (Figure 2).

Clinical outcome assessments illustrated no difference between groups. There was no difference in time of white blood cell count or temperature return to normal; clinical response at day 2, day 7, or end of treatment; or antibiotic-related ICU and total length of stay (Table 2). The cost of treatment of A. baumannii bacteremia is high regardless of antimicrobial agent, with median antibiotic costs for ampicillin-sulbactam equal to $500 (range $50-1220) compared with $1500 (range $220-7520) for imipenem-cilastatin (p=0.0002). Median cost of hospital-ization of an ampicillin-sulbactam-treated patient was $30,000 (range $9600-177,000) versus $43,200 (range $13,200-178,000) for an imipenem-cilastatin-treated patient.

Forty-four percent of imipenem-cilastatin-treated patients and 37% of ampicillin-sulbactam-treated patients received combination therapy with an aminoglycoside. Analysis of these variables led to several interesting findings. Patients who received imipenem-cilastatin with another agent had a significantly longer total length of stay than those given monotherapy (median 57 vs 33 days, p=0.03), whereas there were no significant differences in clinical outcomes between ampicillin-sulbactam combination and monotherapy. Compared with patients who received ampicillin-sulbactam monotherapy, those who received imipenem-cilastatin combination therapy had longer ICU stays (median 36 vs 17 days, p=0.04), total length of stay (median 57 vs 27 days, p=0.006), and higher hospital and antibiotic costs. Antibiotic-related length of stay was significantly shorter (median 8 vs 13 days, p=0.008) for patients who received ampicillin-sulbactam plus an aminoglycoside compared with imipenem-cilastatin alone.
This is a part of article Cipro - investigation results. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog